Remedent (REMI) Short Interest Ratio & Short Volume

Short interest is the volume of Remedent shares that have been sold short but have not yet been covered or closed out. As of February 15th, investors have sold 100 shares of REMI short. Learn More on Remedent's current short interest.

Here is how the short interest of companies in the sector of "medical" compare to Remedent: Endonovo Therapeutics, Inc. (0.00%), Virax Biolabs Group Limited (0.17%), Biodexa Pharmaceuticals Plc (5.18%), Baudax Bio, Inc. (1.11%), GlobeStar Therapeutics Co. (0.01%), TC Biopharm (Holdings) Plc (30.07%), Vyant Bio, Inc. (0.67%), Evelo Biosciences, Inc. (2.11%), SciSparc Ltd. (24.15%), Comera Life Sciences Holdings, Inc. (2.38%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Super Micro Computer, Inc. ($5.32 billion), T-Mobile US, Inc. ($4.38 billion), General Motors ($3.76 billion), Occidental Petroleum Co. ($3.08 billion), Charter Communications, Inc. ($2.65 billion), Coinbase Global, Inc. ($2.62 billion), Tractor Supply ($2.52 billion), Moderna, Inc. ($2.19 billion), Rivian Automotive, Inc. ($1.84 billion), and Royal Caribbean Cruises Ltd. ($1.78 billion). View all of the most shorted stocks.

Short selling REMI is an investing strategy that aims to generate trading profit from Remedent as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Remedent occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of REMI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including REMI, twice per month. The most recent reporting period available is February, 15 2024.